| Longitudinal analysis of point mutations of the N-ras proto-oncogene in patients with myelodysplasia using archived blood smears. | None |
| Absence of point mutation of N-ras oncogene in bone marrow cells with aplastic anemia. | None |
| Repressible transgenic model of NRAS oncogene-driven mast cell disease in the mouse. | None |
| Pathway- and expression level-dependent effects of oncogenic N-Ras: p27(Kip1) mislocalization by the Ral-GEF pathway and Erk-mediated interference with Smad signaling. | None |
| the loss of the proto-oncogene Nras in certain cellular contexts can promote malignant tumor progression | None |
| Enzymatic amplification involving glycosyltransferases forms the basis for the increased size of asparagine-linked glycans at the surface of NIH 3T3 cells expressing the N-ras proto-oncogene. | None |
| Oncogenic K-RAS subverts the antiapoptotic role of N-RAS and alters modulation of the N-RAS:gelsolin complex. | None |
| An RNA G-quadruplex in the 5 UTR of the NRAS proto-oncogene modulates translation. | None |
| N-ras oncogene-induced gene expression in human hematopoietic progenitor cells: upregulation of p16INK4a and p21CIP1/WAF1 correlates with myeloid differentiation. | None |
| Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice. | None |
| Modulatory effect of environmental endocrine disruptors on N-ras oncogene expression in the hermaphroditic fish, Kryptolebias marmoratus. | None |
| CDC25A phosphatase: a rate-limiting oncogene that determines genomic stability. | None |
| restricting CDC25A can limit tumorigenesis induced by the HER2/neu-RAS oncogenic pathway without compromising normal cell division or viability [review] | None |
| AML patients carrying mutRAS benefit from higher cytarabine doses more than wtRAS patients. This seems to be the first example of an activating oncogene mutation favorably modifying response to higher drug doses in AML. | None |
| Position and stability are determining factors for translation repression by an RNA G-quadruplex-forming sequence within the 5 UTR of the NRAS proto-oncogene. | None |
| [Analysis of changes induced by oncogene N-RAS expression in pattern and distribution of pseudopodial activity of fibroblasts]. | None |
| in immortalized mouse melanocytes the consequences of the activation of these three pathways, Raf, PI3K and Ral, alone and in combination, as compared with the full transforming phenotype observed with the expression of oncogenic NRasQ61K. | None |
| Palmitoylation of oncogenic NRAS is essential for leukemogenesis. | None |
| palmitoylation is an essential process for NRAS leukemogenesis and suggests that the development of therapies targeting RAS palmitoylation may be effective in treating oncogenic NRAS-associated malignancies. | None |
| Ras induces ARC in epithelial cancers, and ARC plays a role in the oncogenic actions of Ras | None |